RAQUEL
RIVERA DÍAZ
Profesora asociada de Ciencias de la Salud
Publicacions (171) Publicacions de RAQUEL RIVERA DÍAZ
2024
-
Dose reduction is a feasible strategy in patients with plaque psoriasis who achieve sustained response with secukinumab: a retrospective, multicenter cohort study in daily practice setting
International Journal of Dermatology, Vol. 63, Núm. 4, pp. 503-511
-
Efficacy of Risankizumab in Patients with Suboptimal Response or Failure to Ustekinumab: A Multicenter Retrospective Study in Spain
Dermatologic Therapy, Vol. 2024
-
Family Planning Concerns Among Women With Psoriasis: A Descriptive, Cross-Sectional, Multicenter Study
Actas Dermo-Sifiliograficas, Vol. 115, Núm. 1, pp. 10-20
-
Four-year maintenance of complete skin clearance with bimekizumab in 10 Spanish patients from the BE RADIANT trial
Actas Dermo-Sifiliograficas
-
Improvements in the Management of Patients With Generalized Pustular Psoriasis in Spain: Recommendations From a Group of Experts
Actas Dermo-Sifiliograficas, Vol. 115, Núm. 8, pp. 801-813
-
No tuberculosis reactivations in psoriasis patients initiating new generation biologics despite untreated latent tuberculosis infection: Multicenter case series of 35 patients
Journal of the European Academy of Dermatology and Venereology
-
Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice
Journal of the European Academy of Dermatology and Venereology, Vol. 38, Núm. 9, pp. 1783-1790
-
Pityriasis Rubra Pilaris: A Multicentric Case Series of 65 Spanish Patients
Actas Dermo-Sifiliograficas, Vol. 115, Núm. 8, pp. 761-765
-
Psoriasis Severity, Health-Related Quality of Life, Work Productivity, and Activity Impairments Among Patients With Moderate to Severe Psoriasis Receiving Systemic Treatment: Real-World Data From Clinical Practice in Spain
Actas Dermo-Sifiliograficas, Vol. 115, Núm. 1, pp. 1-9
-
Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study
Actas Dermo-Sifiliograficas
-
Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry
British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363
-
Validation of the Spanish Version of the PURE-4 Questionnaire for the Early Detection of Psoriatic Arthritis in Psoriatic Patients
Actas Dermo-Sifiliograficas, Vol. 115, Núm. 7, pp. 654-662
2023
-
Anti-Interleukin 23 Biologic Are Mostly Effective and Safe in Psoriatic Patients Who Failed Anti-Interleukin 17. A Real-Life, Retrospective 52-Week Experience
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 4, pp. T363-T365
-
Anti-Interleukin 23 Biologic Are Mostly Effective and Safe in Psoriatic Patients Who Failed Anti-Interleukin 17. A Real-Life, Retrospective 52-Week Experience
Actas Dermo-Sifiliograficas, Vol. 114, Núm. 4, pp. 363-365
-
Apremilast treatment of plaque psoriasis (PsO) after systemic therapy in Spanish clinical practice: Data from the APPROPRIATE study
JEADV Clinical Practice, Vol. 2, Núm. 3, pp. 488-501
-
Comorbilidades en las psoriasis pustulosas
Piel, Vol. 38, Núm. 8, pp. 525-529
-
Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study
BMJ open, Vol. 13, Núm. 7, pp. e075197
-
Effectiveness and safety of brodalumab in the treatment of plaque, scalp and palmoplantar psoriasis: A multicentre retrospective study in a Spanish population
Australasian Journal of Dermatology, Vol. 64, Núm. 4, pp. e317-e326
-
Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 12, pp. 2517-2525
-
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: Results from a 52-Week Open-Label Phase IV Clinical Trial (DIMESKIN 1)
Dermatology and Therapy, Vol. 13, Núm. 1, pp. 329-345